Global Oncology Index: Mapping Disparities in Cancer Care Across Globe

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical oncology Pub Date : 2026-12-01 Epub Date: 2026-10-01 DOI:10.1016/j.clon.2026.104355

N. Ranjan

{"title":"Global Oncology Index: Mapping Disparities in Cancer Care Across Globe","authors":"N. Ranjan","doi":"10.1016/j.clon.2026.104355","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>Cancer is a leading global health challenge, with 20 million new cases and 10 million deaths reported in 2022 (GLOBOCAN). Disparities in cancer care, driven by socioeconomic status and healthcare infrastructure, result in higher mortality in low- and middle-income countries (LMICs). The Global Oncology Index (GOI) aims to quantify these disparities and guide targeted interventions.</div></div><div><h3>Materials and Methods</h3><div>The 2025 GOI was developed for 141 countries using incidence-mortality factors from GLOBOCAN 2022 and radiotherapy (RT) infrastructure from the International Atomic Energy Agency (IAEA) register, as radiation is an indispensable part of cancer therapy for around 50% of patients, and RT machine related details were possible to retrieve reliably from the IAEA register, unlike those of surgical and chemotherapeutical centres The GOI formula, [(Incidence age-standardized rate (ASR) – Mortality ASR)/Mortality ASR] × RT centers per million population, integrates cancer burden with treatment capacity. Correlation with Human Development Index (HDI) was assessed.</div></div><div><h3>Results</h3><div>GOI scores ranged from 22.29 (United States) to 0.006 (Ethiopia). High-income countries, including Australia (17.69) and Japan (14.81), led the rankings, while LMICs in Africa and Asia (eg Yemen: 0.007) ranked lowest. Countries are categorized into very low, low, medium, and high GOI country depending on percentile values. Very low GOI countries have a GOI of less than 0.17 (25th percentile), low GOI countries have a GOI between 0.17 and 0.889 (25th-50th percentile), medium GOI countries have a GOI between 0.89 and 2.329 (50th-75th percentile) and high GOI countries have a GOI value between 2.33 or more (>75th percentile). A significant positive correlation (r = 0.574, <em>P</em> < .001) was also observed between GOI and HDI, highlighting socioeconomic influences on oncology outcomes.</div></div><div><h3>Conclusion</h3><div>The GOI underscores global oncology disparities, emphasizing the need for enhanced RT infrastructure and early detection in LMICs. While RT-focused, the index may overlook other treatment modalities, suggesting future refinements to improve comprehensiveness.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"60 ","pages":"Article 104355"},"PeriodicalIF":2.5000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0936655526003262","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

Cancer is a leading global health challenge, with 20 million new cases and 10 million deaths reported in 2022 (GLOBOCAN). Disparities in cancer care, driven by socioeconomic status and healthcare infrastructure, result in higher mortality in low- and middle-income countries (LMICs). The Global Oncology Index (GOI) aims to quantify these disparities and guide targeted interventions.

Materials and Methods

The 2025 GOI was developed for 141 countries using incidence-mortality factors from GLOBOCAN 2022 and radiotherapy (RT) infrastructure from the International Atomic Energy Agency (IAEA) register, as radiation is an indispensable part of cancer therapy for around 50% of patients, and RT machine related details were possible to retrieve reliably from the IAEA register, unlike those of surgical and chemotherapeutical centres The GOI formula, [(Incidence age-standardized rate (ASR) – Mortality ASR)/Mortality ASR] × RT centers per million population, integrates cancer burden with treatment capacity. Correlation with Human Development Index (HDI) was assessed.

Results

GOI scores ranged from 22.29 (United States) to 0.006 (Ethiopia). High-income countries, including Australia (17.69) and Japan (14.81), led the rankings, while LMICs in Africa and Asia (eg Yemen: 0.007) ranked lowest. Countries are categorized into very low, low, medium, and high GOI country depending on percentile values. Very low GOI countries have a GOI of less than 0.17 (25th percentile), low GOI countries have a GOI between 0.17 and 0.889 (25th-50th percentile), medium GOI countries have a GOI between 0.89 and 2.329 (50th-75th percentile) and high GOI countries have a GOI value between 2.33 or more (>75th percentile). A significant positive correlation (r = 0.574, P < .001) was also observed between GOI and HDI, highlighting socioeconomic influences on oncology outcomes.

Conclusion

The GOI underscores global oncology disparities, emphasizing the need for enhanced RT infrastructure and early detection in LMICs. While RT-focused, the index may overlook other treatment modalities, suggesting future refinements to improve comprehensiveness.

查看原文本刊更多论文

全球肿瘤指数：绘制全球癌症护理的差异。

目标：癌症是一项主要的全球健康挑战，2022年将报告2000万新病例和1000万死亡病例（GLOBOCAN）。受社会经济地位和卫生保健基础设施影响，癌症治疗方面的差异导致中低收入国家的死亡率较高。全球肿瘤学指数（GOI）旨在量化这些差异并指导有针对性的干预措施。材料和方法：2025年GOI是为141个国家制定的，使用GLOBOCAN 2022的发病率-死亡率因子和国际原子能机构（IAEA）登记册中的放射治疗（RT）基础设施，因为辐射是约50%患者癌症治疗不可或缺的一部分，与手术和化疗中心不同，RT机器相关细节可以从IAEA登记册中可靠地检索到。[（发病率年龄标准化率(ASR) -死亡率ASR）/死亡率ASR] ×每百万人口的放疗中心，综合了癌症负担与治疗能力。评估与人类发展指数（HDI）的相关性。结果：GOI评分从22.29（美国）到0.006（埃塞俄比亚）不等。包括澳大利亚（17.69分）和日本（14.81分）在内的高收入国家名列前茅，而非洲和亚洲的中低收入国家（如也门：0.007分）排名最低。根据百分位数，国家被分为非常低、低、中和高GOI国家。极低政府指数国家的政府指数低于0.17（第25百分位数），低政府指数国家的政府指数在0.17至0.889之间（第25 -50百分位数），中等政府指数国家的政府指数在0.89至2.329之间（第50 -75百分位数），高政府指数国家的政府指数在2.33或更高（第70 -75百分位数）。GOI和HDI之间也观察到显著的正相关（r = 0.574, P < 0.001），突出了社会经济对肿瘤预后的影响。结论：GOI强调了全球肿瘤学的差异，强调了在中低收入国家加强RT基础设施和早期检测的必要性。虽然以rt为重点，但该指数可能忽略了其他治疗方式，建议未来改进以提高全面性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical oncology 医学-肿瘤学

CiteScore

5.20

自引率

8.80%

发文量

332

审稿时长

40 days

期刊介绍： Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.